Camrelizumab or famitinib for cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at how well camrelizumab or famitinib (alone or with other treatments) work for cervical cancer. It aims to gather real-world information to help guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with cervical cancer (confirmed by biopsy).
- You are receiving or will receive treatment with camrelizumab or famitinib, either alone or with other drugs.
- If you can become pregnant, you agree to use effective birth control and avoid donating eggs during treatment and for a few months after.
- You are not pregnant or breastfeeding.
- You are not currently in another clinical trial that involves other treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing two different doses of a targeted pill (famitinib) combined with an immunotherapy drug (camrelizumab) for cervical cancer that has come back or spread and has not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of three drugs—camrelizumab (an immunotherapy that helps your immune system fight cancer), famitinib (a targeted therapy that blocks blood vessel growth to tumors), and standard chemotherapy—for cervical cancer that has come back or spread and cannot be removed with surgery or radiation. The goal is to see if this combination is safe and effective.
This study tests a combination of two drugs (camrelizumab and famitinib) given after surgery for early-stage cervical cancer. The goal is to see if this treatment helps keep the cancer from returning. It is for people who have not had any other cancer treatment yet.
This trial tests a combination of two drugs—camrelizumab (an immunotherapy) and famitinib (a targeted therapy)—for people with rare head and neck tumors that cannot be removed by surgery or have spread. It may be an option if you have not had a prior PD-1 inhibitor and have had at most one prior systemic treatment.
This trial tests whether giving chemotherapy combined with camrelizumab (a drug that helps the immune system fight cancer) before surgery can help women with early-stage cervical cancer who want to preserve their fertility. It is for patients whose tumors show a protein called PD-L1.
This trial tests whether adding a targeted therapy pill (famitinib) to standard chemo plus an immunotherapy (camrelizumab) can shrink triple negative breast cancer before surgery. It may help people with earlier-stage disease who have not had certain prior treatments.
Hear when a new Cervical Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.